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Schizophrenia relapse, patient considerations, 
and potential role of lurasidone
Leslie Citrome
Department of Psychiatry and 
Behavioral Sciences, New York 
Medical College, valhalla, NY, USA
Abstract: When treating persons with schizophrenia, delaying time to relapse is a main goal. 
Antipsychotic medication has been the primary treatment approach, and there are a variety of 
different choices available. Lurasidone is a second-generation (atypical) antipsychotic agent 
that is approved for the treatment of schizophrenia and bipolar depression. Three long-term 
studies of lurasidone have examined time to relapse in persons with schizophrenia, including a 
classic placebo-controlled randomized withdrawal study and two 12-month active comparator 
studies (vs risperidone and vs quetiapine extended-release). Lurasidone 40–80 mg/d evidenced 
superiority over placebo (number needed to treat [NNT] vs placebo for relapse, 9). Lurasidone 
40–160 mg/d was noninferior to quetiapine extended-release 200–800 mg/d on the outcome 
of relapse, and was superior on the outcome of avoidance of hospitalization (NNT 8) and the 
outcome of remission (NNT 7). Lurasidone demonstrated a lower risk for long-term weight gain 
than the active comparators. Demonstrated differences in tolerability profiles among the different 
choices of antipsychotics make it possible to attempt to match up an individual patient to the 
best choice for such patient based on past history of tolerability, comorbidities, and personal 
preferences, potentially improving adherence.
Keywords: antipsychotic, lurasidone, relapse, tolerability, schizophrenia, weight gain
Introduction
Optimal management of schizophrenia requires adequate symptom control and 
avoidance of exacerbation or relapse. Unfortunately, relapse is common, with an 
estimate of 80% of patients experiencing a relapse in their first 5 years of treatment.1 
Delaying time to relapse is a primary goal when using antipsychotic medication, and 
may mitigate against further decline.2 Lifelong use of antipsychotic medication is thus 
required.3 Unfortunately, antipsychotic medications are associated with a myriad of 
adverse effects.4,5 Demonstrated differences in tolerability profiles among the different 
choices of antipsychotics6 make it possible to attempt to match up an individual patient 
to the best choice for such patient based on past history of tolerability, comorbidities, 
and personal preferences.7,8
Lurasidone is a second-generation (atypical) antipsychotic agent that has demon-
strated efficacy in the treatment of patients with schizophrenia, and it is approved as 
such in the United States, Canada, the European Union, Switzerland, and Australia; 
it is also approved in the United States and Canada for the treatment of major depres-
sive episodes associated with bipolar I disorder as either a monotherapy or adjunc-
tive therapy with lithium or valproate.9 Lurasidone’s pharmacodynamic profile is 
distinguished by its relatively high affinity for serotonin 5-HT7 receptors and its 
partial agonist activity at 5-HT1A receptors, together with being a full antagonist at 
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dopamine D2 and serotonin 5-HT2A receptors.9 Lurasidone’s 
pharmacokinetic profile permits once-daily dosing, and 
administration needs to be with food; it is recommended that 
lurasidone be taken once daily in the evening, with a meal or 
within 30 minutes after eating.9 Metabolism is primarily via 
CYP3A4 and, consequently, its use is contraindicated in the 
presence of strong inhibitors or inducers of CYP3A4 such as 
ketoconazole or rifampin, respectively.9 Lurasidone appears 
associated with minimal effects on body weight and low risk 
for clinically meaningful alterations in glucose, lipids, or 
electrocardiogram parameters.9
This review examines the lurasidone data regarding 
relapse prevention in persons with schizophrenia, specifically 
appraising the results from double-blind controlled trials.
Methods
A literature search was conducted on June 14, 2016, using 
the following terms “lurasidone AND relapse” using the US 
National Library of Medicine PubMed.gov resource. A total 
of 22 records were found, of which three were primary 
reports of double-blind randomized trials,10–12 and one was an 
economic evaluation13 of one of the studies reported.11 One 
of the studies was a classic randomized withdrawal placebo-
controlled relapse prevention study,12 whereas the other two 
studies compared lurasidone with quetiapine extended-release 
(XR)11 and risperidone.10 These reports,10–12 together with any 
study results posted on the ClinicalTrials.gov registry, were 
the principal information sources for this review.
Results
Table 1 provides an overview of the three relevant studies: 
Citrome et al,10 Loebel et al,11 and Tandon et al.12 Doses of 
lurasidone tested were in the range of 40–160 mg/d.
NCT00641745
The first published randomized double-blind study of lur-
asidone that included relapse as an outcome measure was 
a 12-month safety and tolerability study where 629 per-
sons, aged between 18 and 75 years, with clinically stable 
schizophrenia or schizoaffective disorder, were allocated to 
receive flexibly dosed lurasidone 40–120 mg/d (n=427) or 
risperidone 2–6 mg/d (n=202).10 The study was conducted 
at 68 study centers located primarily in the United States 
(40 sites; approximately two-thirds of all participants), but 
also recruited patients in Argentina, Brazil, Chile, Croatia, 
Israel, South Africa, and Thailand. Inclusion criteria included 
the following: duration of illness 1 year; in a nonacute 
phase of illness for 8 weeks; no change in antipsychotic 
medications, other than minor dose adjustments for 
tolerability purposes, for 6 weeks before screening; no 
hospitalization for psychiatric illness for 8 weeks; and 
moderate or less severity rating on the Positive and Negative 
Syndrome Scale (PANSS) items of delusions, conceptual 
disorganization, hallucinations, and unusual thought content. 
Among the exclusion criteria were treatment with risperidone 
within 6 weeks before baseline, or a history of a poor or an 
inadequate response, or intolerability to risperidone. Patients 
who had been treated with a stable dose of antidepressants 
or mood stabilizers for 1 month before the baseline visit 
were allowed to continue this treatment during the study; 
otherwise, subjects were not permitted to begin treatment 
with these agents after the screening visit. Although the 
primary outcome measure was the number of participants 
with adverse events, efficacy outcomes included relapse rate, 
PANSS total score, and the Clinical Global Impressions-
Severity (CGI-S) score. Relapse was defined as worsening of 
the PANSS total score by 30% from baseline and CGI-S 3; 
rehospitalization for worsening of psychosis; or emergence 
of suicidal ideation, homicidal ideation, and/or risk of harm 
to self or others.
Relapse
A small proportion of subjects in the study experienced 
a relapse (114/608, 19%). The rate of relapse among 
lurasidone-treated patients was 20% (82/410), and that for 
risperidone-treated patients, 16% (32/198), yielding a number 
needed to treat (NNT) value of 27 (not statistically significant 
[ns]) in favor of risperidone (for a brief overview of NNT, 
see Box 1). For both treatment groups, the Kaplan–Meier 
estimates of the probability of relapse were less than 0.5 
at month 12; therefore, the median survival time to relapse 
could not be calculated for either treatment group. The relapse 
hazard ratio comparing lurasidone vs risperidone was 1.31 
(95% confidence interval [CI]: 0.87–1.97; P=0.194). Because 
the study was powered to test the noninferiority of lurasi-
done relative to risperidone on the basis of the assumption 
of expected relapse rates of 35% for both treatment groups 
after 1 year, the noninferiority test was uninterpretable 
because the actual relapse rates were substantially lower 
than initially predicted.
Other efficacy outcomes
The PANSS total score decreased from baseline to month 12 
in both the lurasidone group (-4.7; 95% CI: -6.4 to -3.0) and 
the risperidone group -6.5; 95% CI: -8.8 to -4.3), with no 
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in the PANSS total scores at any time during the 12-month 
double-blind treatment period. Similarly, the CGI-S score 
decreased from baseline to month 12 similarly in both the 
lurasidone group (-0.4; 95% CI: -0.5 to -0.3) and the ris-
peridone group (-0.4; 95% CI: -0.5 to -0.2).
Tolerability outcomes
The three most frequent adverse events among the lurasidone-
treated patients (vs risperidone) were nausea (17% vs 11%), 
insomnia (16% vs 13%), and sedation (15% vs 14%); the 
three most frequent adverse events in the risperidone-treated 
patients (vs lurasidone) were increased weight (20% vs 9%), 
somnolence (18% vs 14%), and headache (15% vs 10%). 
The rates of akathisia reported by patients as an adverse 
event were 14% and 8% in the lurasidone and the risperi-
done groups, respectively; rates of discontinuation because 
of akathisia were low in both groups (1.0% of lurasidone 
patients and 1.5% of risperidone patients). Risperidone 
was more likely to result in body weight gain of 7%, as 
observed in 14% of subjects receiving risperidone vs 7% for 
lurasidone-treated patients. Endpoint change in prolactin was 
also higher with the risperidone group. All-cause discontinu-
ation rates were higher for lurasidone vs risperidone: 269/419 
(64%) for lurasidone and 105/202 (52%) for risperidone 
in the safety population, resulting in an NNT of 9 (95% 
CI: 5–26) in favor of risperidone. However, there were no 
significant treatment differences for the time to discontinu-
ation because of insufficient clinical response, an adverse 
event, or withdrawal of consent.
NCT00789698
A second long-term study that contrasted lurasidone with 
an active comparator was a 12-month double-blind exten-
sion11 to a 6-week placebo-controlled acute treatment trial.14 
Enrolled were 292 persons with schizophrenia, aged between 
18 and 75 years, who received either flexibly dosed lurasi-
done 40–160 mg/d (n=207) or quetiapine XR 200–800 mg/d 
(n=85).11 The study was conducted at 58 centers in six 
countries, with approximately one-quarter of all participants 
being from the United States. The primary relapse prevention 
analysis population was defined as all subjects who were 
randomized to either once-daily fixed doses of lurasidone 
(80 or 160 mg) or quetiapine XR 600 mg in the initial 6 week 
acute treatment study and who met clinical response criteria 
at the end of that study. Response was defined as 20% 
reduction in PANSS total score from acute study baseline 
and a CGI-S 4. A total of 139 subjects receiving lurasidone 
and 79 subjects receiving quetiapine XR were included in 
the primary noninferiority analysis for relapse prevention. 
Relapse was defined as worsening of 30% in the PANSS 
total score from day 42 of the initial acute treatment study and 
a CGI-S 3; rehospitalization for worsening of psychosis; 
or emergence of suicidal ideation, homicidal ideation, and/
or risk of harm.
Relapse
The rate of relapse among lurasidone-treated patients was 
21% (29/139), and that for quetiapine-treated patients, 27% 
(21/79), yielding a number NNT of 18 (not statistically 
Box 1 what is NNT?
An NNT is a measure of effect size that is clinically intuitive. NNT answers the question: “How many patients would you need to treat with 
intervention A instead of intervention B before you would expect to encounter one additional positive outcome of interest?” For the outcome 
of avoidance of relapse, an NNT of “x” for a test medication vs placebo would mean you would have to treat “x” number of patients with the 
test medication instead of with placebo before expecting to avoid one additional relapse. The lower the NNT, the more robust the intervention 
is when compared to the alternative. NNT is a different concept than P-value, which relates to “statistical” significance. NNT is a measure of 
“clinical” significance. A P-value, even as low as P0.00001, does not necessarily mean that a result is clinically relevant. To determine possible 
clinical relevance (ie, clinical significance) effect size, such as NNT, needs to be evaluated.
NNT is simple to calculate:
A = frequency of outcome for intervention A
B = frequency of outcome for intervention B
NNT =1/(A–B), rounded up to a whole number
For example, if giving a test medication results in relapse of 25% over a 12-month period and giving placebo results in relapse of 50% over a 12-
month period, NNT for avoidance of relapse for the test medication vs placebo is 1/(50%–25%)=1/(0.50–0.25)=1/(0.25)=4. Thus, for every four 
persons given the test medication instead of placebo, you would expect to avoid one additional relapse event.
A rule of thumb is that NNT values vs placebo 10 denote potentially useful interventions. Most psychotropic medications for most indications 
have NNT values between 3 and 9 for clinically relevant definitions of response or efficacy. The lower the NNT, the more often desired 
outcomes are encountered.
An additional tutorial for the use of NNT can be found at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140623/ and guidance on interpretation 
is further available at http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12142/full. Both of these resources are free to access.
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Lurasidone and relapse prevention
significant) in favor of lurasidone. For both treatment groups, 
the Kaplan–Meier estimates of the probability of relapse were 
less than 0.5 at month 12; therefore, the median survival 
time to relapse could not be calculated for either treatment 
group. The relapse hazard ratio comparing lurasidone vs 
quetiapine was 0.73 (95% CI: 0.41–1.30), demonstrating 
noninferiority.
Other efficacy outcomes
An advantage was found for lurasidone regarding hospital-
ization risk. The Kaplan–Meier estimate of the probability 
of hospitalization at 12 months was significantly lower 
for lurasidone vs quetiapine XR, at 10% vs 23% (NNT 8; 
95% CI: 5–37; P0.05), resulting in a hazard ratio of 0.43 
(95% CI: 0.19–1.0). More patients on lurasidone achieved 
remission, as defined by Andreasen et al,15 compared to 
patients receiving quetiapine XR with rates of 62% vs 46%, 
respectively, resulting in an NNT of 7 (95% CI: 4–52). There 
was significantly greater change in the PANSS total score 
from the 12-month study baseline for lurasidone-treated 
patients than for patients treated with quetiapine XR (-5.0 
vs +1.7); however, changes in CGI-S scores were similar.
Tolerability outcomes
The three most frequent adverse events in the lurasidone-
treated group were akathisia (13%), headache (11%), and 
insomnia (8%); the three most frequent adverse events in 
the quetiapine XR group were worsening of schizophrenia 
(15%), insomnia (9%), and headache (9%). The rates of 
akathisia reported by patients as an adverse event were 11% 
and 2% in the lurasidone and the quetiapine XR groups, 
respectively (and 13% among those initially on placebo 
in the parent study and then switched to lurasidone in the 
12-month study). Quetiapine XR was more likely to result in 
weight gain of 7%, with this outcome observed in 27.5% 
of subjects receiving quetiapine XR vs 14% for lurasidone-
treated patients at 6 months, and 15% vs 11.5% at 12 months, 
respectively, for observed cases. Rates of discontinuation due 
to adverse events were similar: 7% for lurasidone-treated 
patients and 5% for patients receiving quetiapine XR.
Other publications
Additional publications identified in PubMed.gov by search-
ing on the ClinicalTrials.gov identifier NCT00789698 have 
reported on improved cognitive performance in patients 
treated with lurasidone compared to quetiapine XR.16,17 
An economic impact study has also been published, demon-
strating cost savings with lurasidone over quetiapine, driven 
by the lower relapse-related hospitalization rates observed 
with lurasidone.13
NCT01435928
A classic randomized withdrawal study has been published 
where 285 persons with schizophrenia, aged 18–75 years, 
met protocol-specified stabilization criteria and were random-
ized to receive lurasidone 40–80 mg/d (n=144) or placebo 
(n=141) for up to 28 weeks.12 The study was conducted at 
71 sites in seven countries, with 45 of the study sites located 
in the United States and comprising approximately 70% of all 
participants. Subjects were initially enrolled in an open-label 
stabilization phase where 676 acutely ill patients received 
12–24 weeks of treatment with lurasidone at a starting dose 
of 40 mg/d, with flexible dosing permitted after 3 days up 
until the last 4 weeks of the stabilization period, during 
which no dose adjustments were permitted. Treatment with 
antidepressant medications or mood stabilizers was allowed 
in patients who had been taking a stable dose for 30 days 
prior to the open-label stabilization phase baseline; however, 
initiation or increase in dosage of these medications during 
the study was prohibited. The protocol-specified stabiliza-
tion criteria were that subjects maintained clinical stability 
for 12 weeks during the open-label stabilization phase 
and had remained on a stable dose of lurasidone for 4 weeks 
prior to randomization. Clinical stability was defined as a 
PANSS total score 70, with PANSS item scores 4 on 
all positive subscale items and the general psychopathology 
item for uncooperativeness, and a CGI-S score 4. There 
was some flexibility to retain subjects if they had temporary 
increases in their total PANSS score (up to 80), CGI-S of 4, 
or a PANSS positive item of 5; two such events were allowed 
after initial attainment of the stability criteria, except dur-
ing the last 4 weeks of the open-label stabilization phase. 
Once randomized, lurasidone dose was the same as the final 
open-label dose but adjustments within the range of lurasi-
done 40–80 mg/d were subsequently allowed. Relapse was 
defined as an increase of 25% from double-blind baseline 
in PANSS total score and CGI-S worsening of 1 point for 
two consecutive visits no more than 10 days apart; at any 
single visit, a PANSS item score of 5 (moderately severe) 
on hostility or uncooperativeness, or a PANSS item score 
of 5 on two or more items of unusual thought content, delu-
sions, conceptual disorganization, or hallucinatory behavior; 
initiation of supplemental treatment with an antipsychotic 
medication other than lurasidone, an increased dose of an 
antidepressant or mood stabilizer, an increase in lorazepam 
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3 days, or electroconvulsive therapy; insufficient clinical 
response or exacerbation of underlying disease reported as 
an adverse event, as determined by the study investigator; 
deliberate self-injury or repeated aggressive behavior, active 
suicidal or homicidal ideation or attempt; or psychiatric 
hospitalization due to worsening schizophrenia.
Relapse
The rate of relapse among lurasidone-treated patients was 
30% (43/144), and that for placebo-treated patients, 41% 
(58/141), yielding an NNT of 9 (95% CI: 5–426) in favor of 
lurasidone. The Kaplan–Meier estimates of the probability of 
relapse at week 28 were 42% for patients receiving lurasidone 
and 51% for the placebo group, with a median survival time 
to relapse of about 28 weeks for subjects receiving placebo, 
and it was not calculable for patients randomized to continue 
treatment with lurasidone. The relapse hazard ratio compar-
ing lurasidone vs placebo was 0.66 (95% CI: 0.45–0.98), 
demonstrating superiority.
Other efficacy outcomes
Patients in the placebo-treated group evidenced worsening in 
PANSS total and CGI-S scores compared to patients receiv-
ing lurasidone. Of note, differences in efficacy outcomes were 
noted when comparing US with non-US sites; lurasidone 
significantly delayed time to relapse in the non-US subgroup 
(n=85, log-rank test, P=0.010) but not in the US subgroup 
(n=200, log-rank test, P=0.414).
Tolerability outcomes
In the open-label stabilization phase, the most common 
adverse events were akathisia (14%), headache (11%), and 
nausea (10%). In the double-blind phase, the three most 
frequent adverse events in the lurasidone-treated group were 
schizophrenia (8%), insomnia (6%), and anxiety or back 
pain (4% each); the three most frequent adverse events in 
the placebo group were schizophrenia (9%), insomnia (7%), 
and headache (3.5%). Rates of akathisia in the double-blind 
phase were 2.1% for subjects receiving lurasidone and 
2.8% for those receiving placebo. The discontinuation rate 
due to adverse events (including the adverse event-related 
relapse criterion of worsening of schizophrenia) during 
the double-blind phase was 14% for lurasidone and 16% 
for placebo. Minimal changes in weight, lipids, glucose, 
and prolactin were observed. Moreover, in the patients 
treated with lurasidone, mean weight change was -0.6 kg 
as observed across the open-label and randomized phases, 
with weight gain 7% and weight loss 7% experienced by 
a similar proportion of patients (17.4% and 16.7%, respec-
tively). All-cause discontinuation rates were 48% and 58%, 
for lurasidone- and placebo-treated subjects, respectively, 
resulting in an NNT of 10 (ns), with a Kaplan–Meier prob-
ability of all-cause discontinuation at the week 28 endpoint 
of 58% for the lurasidone group vs 70% for placebo (log 
rank test, P=0.070).
Discussion
The efficacy of lurasidone for the maintenance treat-
ment of patients with schizophrenia was tested in three 
multicenter, randomized, controlled trials,10–12 including 
a placebo-controlled, randomized withdrawal study.12 
Superiority to placebo and noninferiority to quetiapine 
XR has been evidenced, with an uninterpretable relapse 
outcome when lurasidone was compared with risperidone. 
Doses tested span the range of that available for lurasidone, 
40–160 mg/d; however, the placebo-controlled trial was 
limited to 80 mg/d.12 This is somewhat problematic as it is 
apparent that some patients may require higher doses in the 
face of inadequate response to 80 mg/d.18,19 This limitation 
in lurasidone dose in the placebo-controlled randomized 
withdrawal study, together with possible study-conduct 
problems at US sites (given the lack of signal detection 
in the United States vs outside the United States), may 
have led to the observed effect size that is less robust (and 
less precise) than reported for other similar studies with 
other second-generation antipsychotics (Table 2),20–28 and 
as noted in a meta-analysis of placebo-controlled studies 
of antipsychotic agents for relapse prevention in patients 
with schizophrenia, which found from data published from 
1962 to 2010, across 24 randomized trials, that treatments 
reduced relapse rates at around 1 year (7–12 months) from 
64% (placebo) to 27% (risk ratio: 0.40; 95% CI: 0.33–0.49; 
risk difference: -39%; 95% CI: -46 to -32), for an NNT of 
3.29,30 Figure 1 depicts the NNT vs placebo and 95% CIs for 
the outcome of relapse (or impending relapse) from data 
that have been published (or recently presented) of pivotal 
placebo-controlled randomized withdrawal studies of the oral 
first-line second-generation antipsychotics (there is no avail-
able study for quetiapine immediate-release or risperidone). 
Indirect comparison reveals a degree of overlap for the 95% 
CIs among the agents, including lurasidone vs aripiprazole, 
brexpiprazole, cariprazine, olanzapine, paliperidone, and 
ziprasidone. Although there is no overlap in the 95% CIs 
for lurasidone vs quetiapine XR, this indirect comparison is 
difficult to interpret, particularly in the face of noninferiority 
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Lurasidone and relapse prevention
was directly compared with quetiapine XR.11 An important 
caveat is that randomized withdrawal studies can differ 
substantially in terms of open-label stabilization periods 
(if any), stabilization criteria, length of observation, and 
relapse criteria. The efficacy profile for each alternative also 
needs to be considered within the context of tolerability and 
safety.8 For example, as observed in the relapse-prevention 
studies of lurasidone, although lurasidone was associated 
with generally higher rates of akathisia, quetiapine XR and 
risperidone were more likely to result in weight gain.
The maintenance of a therapeutic response with long-
term use of lurasidone for schizophrenia is also supported 
by several open-label extension studies of up to 22 months in 
duration.31–33 The long-term effect of lurasidone 40–160 mg/d 
on body weight after 12 months of treatment in persons 
with schizophrenia was examined in a pooled analysis 
of 593 observed cases;34 subjects were participants from 
the two 12-month randomized studies reviewed here,10,11 
combined with data from a 22-month open-label extension 
study,31 a 12-month extension study (NCT00088621), a 
Table 2 Placebo-controlled randomized withdrawal studies of first-line oral second-generation antipsychotics in persons with 
schizophrenia
Antipsychotic Length of double-
blind period
N randomized Kaplan–Meier analysis: relapse 
HR vs placebo (95% CI)
Observed relapse 
rates vs placebo
NNT vs placebo 
(95% CI)
Lurasidone12 Up to 28 weeks 285 0.66 (0.45–0.98) 30% vs 41% 9 (5–426)
Aripiprazole20 Up to 26 weeks 310 0.50 (0.35–0.71) 34% vs 57% 5 (3–9)
Asenapine21 Up to 26 weeks 386 Not reported 12% vs 47% 3 (3–4)
Brexpiprazole22 Up to 52 weeks 202 0.29 (Ci not reported) 13.5% vs 38.5% 4 (3–8)
Cariprazine23 Up to 72 weeks 200 0.45 (0.28–0.73) 25% vs 47.5% 5 (3–11)
iloperidone24 Up to 26 weeks 195 0.21 (0.12–0.37) 16.5% vs 54.2%a 3 (2–4)
Olanzapine25 Up to 52 weeks 326 6 month: 0.10 (0.05–0.22) 4% vs 37% 3 (3–5)
Paliperidone26 variable; no set limit 207 Not reported 22% vs 51.5% 4 (3–6)
Quetiapine iR No relevant registration studies available
Quetiapine XR27 Up to 52 weeks 197 interim: 0.16 (0.08–0.34) 12% vs 48.5% 3 (3–4)
Risperidone No relevant placebo-controlled registration studies available
Ziprasidone28 Up to 52 weeks 294 Not reported 34.5% vs 61% 4 (3–8)
Notes: aPersonal Communication, Mallery Mayo, vanda Pharmaceuticals inc., July 13, 2016. The observed relapse rates were not reported in the published paper.
Abbreviations: CI, confidence interval; HR, hazard ratio; NNT, number needed to treat; IR, immediate release; XR, extended-release; N, number.
Figure 1 NNT vs placebo and 95% Cis for the outcome of relapse (or impending relapse) from available data from the pivotal placebo-controlled randomized withdrawal 
studies of the oral first-line second-generation antipsychotics (there is no available study for quetiapine immediate-release or risperidone).



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Japanese 44-week open-label extension of a 8-week double-
blind study, and a Japanese 12-month open-label study that 
enrolled acute patients. Mean baseline weight was 72.8, 
80.8, and 72.4 kg in the lurasidone (n=471), risperidone 
(n=89), and quetiapine XR (n=33) groups, respectively. At 
the end of 1 year, mean weight change was -0.4 kg with 
lurasidone, +2.6 kg with risperidone, and +1.2 kg with que-
tiapine XR. Weight gain 7% was seen in 16%, 26%, and 
15% of patients, while weight loss 7% was observed in 
18.5%, 7%, and 9%, respectively. Lurasidone thus appears 
to have a lower risk for long-term weight gain than some 
other second-generation antipsychotics, and these data are 
consistent with that observed in short-term acute clinical 
trials for both schizophrenia35 and bipolar depression36 and 
in the 24-week open-label extension study for bipolar depres-
sion.37 Body weight is easily monitored during routine office 
visits, and avoiding overweight and obesity is an important 
strategy in managing risk for metabolic syndrome, diabetes, 
and cardiovascular disease.38 Patients with weight gain may 
be less likely to be adherent to their prescribed medications 
as observed in a nationwide survey of 876 US adults with 
schizophrenia and taking antipsychotic medication, where 
about 26% reported bothersome weight gain.39
Studies examining quality-of-life improvements among 
persons with schizophrenia treated with lurasidone have 
been published.40,41 In a 24-week extension32 of an open-label 
6-week switch study,42 health-related quality of life was mea-
sured using the self-reported Personal Evaluation of Transi-
tions in Treatment scale and Short-Form 12 questionnaire; 
improvements were observed on both of these measures, 
including components assessing adherence-related attitude 
and psychosocial functioning.41
No singular medication is perfect for everyone.8 Additional 
choices for antipsychotics for the treatment of schizophrenia 
are also desirable to accommodate the wide range of preexist-
ing tolerability issues that patients may have.43 Consideration 
should also be given to other formulations, such as long-
acting injectables, particularly in the maintenance phase of 
treatment, assuming the suitability of the currently available 
options for the individual person being treated.44
In summary, the overall available data support the use of 
lurasidone for relapse prevention. Long-term safety and toler-
ability mirrors that observed during short-term acute trials, 
with advantages in terms of a more favorable weight gain 
profile than many other available choices,6,7 and consequently 
a lower risk for problematic alterations in lipid profile and 
the development of insulin resistance.
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